GE HealthCare Technologies Inc. (NASDAQ: GEHC) awarded Chief Financial Officer Grogan William K 75,096 shares across two transactions. The reported price was $0 per share, and the resulting share holding was 75,096 shares.
111, Inc. generated RMB2.3 billion in revenue during the three months ended June 30, 2026, down 28.3% from RMB3.2 billion in the prior-year quarter. Marketplace service revenue increased 18.2% year over year during the first half of 2026. The transition followed the divestment of …
Indivior Pharmaceuticals, Inc. (NASDAQ: INDV) declared a specialCash Dividendof $8.13 per share, with payment tied to completion of its merger with Supernus Pharmaceuticals. The distribution is intended for eligible Indivior shareholders and certain holders ofEquityawards, but it remains conditional on the transaction closing.
The office change took effect on September 15, giving the company an updated corporate location and contact number.
PLEXUS CORP (NASDAQ: PLXS) CFO Abuhl David Westen exercised options covering 2,500 shares on September 15, 2026. The transaction left Westen with 2,500 shares, representing about 100.0% of his resulting share holding.
The revised timetable keeps the award subject to the executive’s continuous service through that date.
ROHDE STEPHEN L exercised options for 7,500 shares of Slide Insurance Holdings, Inc. (NASDAQ: SLDE) and sold 7,500 shares on September 14, leaving no reported share holding afterward. The transactions covered both an option exercise and a share sale involving the insurance company.
Alamar Biosciences, Inc. (NASDAQ: ALMR) awarded General Counsel John L. Brottem 29,000 shares at $0 per share. The award occurred on September 14, 2026, and left Brottem holding 29,000 shares.
Autonomix Medical, Inc. (NASDAQ: AMIX) appointed Sandra Kalter as an independent director on September 14, 2026. The addition gives the board expertise in medical-device regulation, clinical matters, quality systems and technology evaluation as Autonomix advances its platform.
Avalyn Pharma Inc. (NASDAQ: AVLN) appointed Robert Meyer, M.D. As an independent Class II director, making him eligible for a $40,000 annual retainer. The board selected Meyer following a recommendation from its Nominating and Corporate Governance Committee.